Trial Search Results

Everolimus in Patients With Pancreatic Neuroendocrine Tumors Metastatic to the Liver Previously Treated With Surgery

This randomized phase II trial studies how well everolimus works in treating patients with pancreatic neuroendocrine tumors metastatic to the liver previously treated with surgery. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving everolimus after surgery may kill any tumors cells that remain.

Stanford is currently not accepting patients for this trial.

Lead Sponsor:

Eastern Cooperative Oncology Group

Collaborator: National Cancer Institute (NCI)

Stanford Investigator(s):


  • Drug: everolimus
  • Other: placebo
  • Other: laboratory biomarker analysis


Phase 2


Inclusion Criteria:

   - Patients must have histologically or pathologically confirmed metastatic low or
   intermediate grade pancreatic neuroendocrine tumor(s) to the liver as per the Klimstra

   - Patients must have recovered from an R0 or R1 resection of all disease (including
   resection of a primary primitive neuroectodermal tumor [PNET] if present); patients
   may have had resection plus microwave or radiofrequency ablation, provided that no
   ablated lesion was >= 5 cm prior to ablation

   - Patients must be within 4 to 8 weeks from the completion of surgery at time of

   - Patients must have paraffin-embedded fixed metastatic tumor tissue available for
   submission for central review; core biopsy or surgical specimens required

   - Patients must have post-operative computed tomography (CT) or magnetic resonance
   imaging (MRI) prior to randomization and =< 4 weeks after completion of surgery to
   confirm disease status; patients must be able to tolerate CT or MRI imaging including
   contrast agents as required for the protocol

   - Patients must NOT have either clinically apparent central nervous system metastases or
   carcinomatous meningitis =< 6 months prior to randomization

   - Women must NOT be pregnant or breast-feeding; all females of childbearing potential
   must have a blood test within 2 weeks prior to randomization to rule out pregnancy

   - Women of child-bearing potential and sexually active males must be strongly advised to
   use an accepted and highly effective method of contraception or abstain from sexual
   intercourse for the duration of their treatment through 8 weeks after their last dose
   of protocol therapy; women of child-bearing potential, sexually active males, and the
   female partners of male participants should be advised of the risk of becoming
   pregnant or fathering a child while receiving protocol treatment; should a woman
   become pregnant while participating in this study, she should inform her treating
   physician immediately; if a man impregnates a woman while participating in this study,
   he should inform his treating physician immediately

   - Prior treatment with sunitinib and/or cytotoxic chemotherapy are allowed provided last
   dose was > 30 days prior to randomization

   - Prior chemoembolization is allowed provided last dose was > 30 days prior to

   - Patients must NOT have received prior everolimus

   - Total bilirubin =< 1.5 X institutional upper limit of normal (ULN)

   - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
   [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
   =< 5 X institutional ULN

   - Serum creatinine =< 1.5 X institutional ULN or creatinine clearance >= 60 mL/min for
   patients with creatinine levels above 1.5 X institutional normal

   - Fasting serum cholesterol =< 300 mg/dL OR =< 7.75 mmol/L AND fasting triglycerides =<
   2.5 x ULN

   - Absolute neutrophil count >= 1,500/mm^3

   - Leukocytes >= 3,000/mm^3

   - Platelets >= 100,000/mm^3

   - Hemoglobin >= 9 g/dL

   - Patients must NOT have ongoing cardiac dysrhythmia of National Cancer Institute (NCI)
   Common Terminology Criteria for Adverse Events (CTCAE) version 4.0 (v4.0) grade >= 2,
   uncontrolled atrial fibrillation of any grade, or corrected QT (QTc) interval > 470

   - Patients with a history of the following within =< 12 months of randomization are not

      - Arterial thromboembolic events

      - Unstable angina

      - Myocardial infarction

   - Patients must NOT have experienced thrombotic events (deep vein thrombosis, pulmonary
   embolism) =< 3 months prior to randomization

   - Patients must NOT have liver disease such as cirrhosis, chronic active hepatitis, or
   chronic persistent hepatitis at randomization; patients at increased risk for
   hepatitis B or hepatitis C must be screened for hepatitis prior to randomization

   - Patients must NOT have history of severely impaired pulmonary function for their age;
   patients with known history of abnormal pulmonary function must have documentation of
   diffusing capacity of the lung for carbon monoxide (DLCO) of > 50% predicted and
   oxygen saturation (SaO2) of > 87% at rest on room air =< 4 weeks prior to

   - Patients with unexplained pulmonary infiltrates must have pulmonary function tests
   within the institutional limits of normal =< 4 weeks prior to randomization

   - Patients with known history of human immunodeficiency virus (HIV) seropositivity are

   - Patients with poorly controlled diabetes mellitus as defined by hemoglobin A1c (HbA1c)
   > 8% despite adequate therapy are ineligible; patients with a known history of
   impaired fasting glucose or diabetes mellitus must have blood glucose and antidiabetic
   treatment monitored closely throughout the trial and adjusted as necessary

   - Patients must NOT have any severe and/or uncontrolled medical conditions such as:

      - Unstable angina pectoris, symptomatic congestive heart failure, myocardial
      infarction =< 6 months prior to randomization, serious uncontrolled cardiac
      arrhythmia, or any other clinically significant cardiac disease

      - Symptomatic congestive heart failure of New York Heart Association class III or

      - Active (acute or chronic) or uncontrolled severe infection, liver disease such as
      cirrhosis, decompensated liver disease, and chronic hepatitis (i.e. quantifiable
      hepatitis B virus [HBV]-deoxyribonucleic acid [DNA] and/or positive hepatitis B
      surface antigen [HbsAg], quantifiable hepatitis C virus [HCV]-ribonucleic acid

      - Active, bleeding diathesis

   - Patients must NOT have previous or concurrent malignancy; exceptions are made for
   patients who meet any of the following conditions:

      - Non-melanoma skin cancer, in situ cervical cancer, breast cancer in situ, or
      superficial bladder cancer (noninvasive papillary carcinoma or carcinoma in
      situ); OR

      - Prior malignancy completely excised or removed and patient has been continuously
      disease free for > 5 years

   - Patients may not be receiving any other investigational agents while on study
   treatment; prior treatment with other investigational agent is allowed provided last
   dose was >= 30 days prior to randomization

   - Patients must NOT have received live attenuated vaccines =< 1 week prior to
   randomization; patients should also be advised not to receive live attenuated vaccines
   during the study and to avoid close contact with others who have received live
   attenuated vaccines; examples of live attenuated vaccines include intranasal
   influenza, measles, mumps, rubella, oral polio, Bacillus Calmette-Guerin (BCG), yellow
   fever, varicella and TY21a typhoid vaccines

   - Patients must NOT be on chronic treatment with corticosteroids or other
   immunosuppressive agents; topical or inhaled corticosteroids are allowed

   - Patients should be advised to avoid drugs or foods that are known potent cytochrome
   P450, family 3, subfamily A, polypeptide 4 (CYP3A4) inhibitors or inducers

   - Patients must NOT have history of allergic reactions attributed to compounds of
   similar chemical or biologic composition to everolimus

   - Patients must NOT have known intolerance or hypersensitivity to everolimus or other
   rapamycin analogs (e.g. sirolimus, temsirolimus)

   - Patients must NOT have absorption issues that would limit the ability to absorb

   - Patients must NOT have a history of non-compliance to medical regimens or who are
   considered potentially unreliable or will not be able to complete the entire study

   - Patients must have Eastern Cooperative Oncology Group (ECOG) performance status =< 1

   - Patients must have life expectancy >= 12 weeks

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Not Recruiting